Rybelsus and the Stomach: Navigating GI Adverse Events of Oral Semaglutide
Rybelsus® (oral semaglutide) represents a major innovation in the treatment of type 2 diabetes, offering patients a GLP-1 receptor agonist in tablet form for the first time. As an incretin mimetic, semaglutide promotes glycemic control through mechanisms such as enhanced insulin secretion, suppressed glucagon release, and delayed gastric emptying. It also supports weight loss and […]
GLP-1 Agonists and Colonoscopy Prep: Updated Guidance for Rybelsus Users
With the growing use of GLP-1 receptor agonists such as Rybelsus® (oral semaglutide) for type 2 diabetes and weight management, clinicians are increasingly faced with questions regarding their safe use around elective procedures, particularly colonoscopy. These agents offer significant metabolic and cardiovascular benefits but are also known to delay gastric emptying, a mechanism that, while […]
Diabetes and the GI Tract: From Gastroparesis to NAFLD
Introduction Diabetes is a systemic disease with well-known effects on the eyes, kidneys, and cardiovascular system, but its impact on the gastrointestinal (GI) tract is often underrecognized. In clinical practice, patients with diabetes frequently report symptoms such as bloating, nausea, reflux, constipation, or alternating bowel habits, yet these complaints are rarely attributed directly to glycemic […]
Pharmacologic Treatment of MASLD/MASH: GLP-1 Agonists, Resmetirom & Beyond
Rebranding NAFLD/NASH → MASLD/MASH: Why the New Terminology Matters In 2023, a major nomenclature shift redefined the landscape of fatty liver disease: NAFLD (nonalcoholic fatty liver disease) became MASLD (metabolic dysfunction-associated steatotic liver disease), and NASH (nonalcoholic steatohepatitis) was renamed MASH (metabolic dysfunction-associated steatohepatitis). This reclassification, endorsed by hepatology societies including the AASLD in its […]